12月18日，卫信康盘中上涨2.05%，截至13:34，报10.94元/股，成交1757.89万元，换手率0.37%，总市 值47.61亿元。 资金流向方面，主力资金净流出338.61万元，大单买入27.43万元，占比1.56%，卖出366.04万元，占比 20.82%。 卫信康今年以来股价涨13.66%，近5个交易日涨1.58%，近20日跌2.53%，近60日跌9.09%。 责任编辑：小浪快报 资料显示，西藏卫信康医药股份有限公司位于西藏自治区拉萨经济技术开发区B区园区南路5号工业中 心4号楼3层，成立日期2006年3月17日，上市日期2017年7月21日，公司主营业务涉及化学药品制剂及其 原料药的研发、生产、销售。主营业务收入构成为：市场服务72.08%，药品27.92%。 卫信康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：多胎概念、维生素、生物 医药、仿制药、小盘等。 截至9月30日，卫信康股东户数1.65万，较上期增加14.14%；人均流通股26333股，较上期减少12.39%。 2025年1月-9月，卫信康实现营业收入8.62亿元，同比减少13.27%；归母净利润2.19亿元，同 ...

一、药物基本情况 药物名称：利多卡因丁卡因乳膏 证券代码：603676 证券简称：卫信康 公告编号：2025-056 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，西藏卫信康医药股份有限公司（以下简称"公司"）全资子公司西藏中卫诚康药业有限公司（以下 简称"西藏中卫诚康"）收到国家药品监督管理局（以下简称"国家药监局"）核准签发的利多卡因丁卡因 乳膏《药物临床试验批准通知书》，现就相关事项公告如下： 截至目前，国内已获得临床批件并完成临床试验申报上市的企业有4家：江苏盈科生物制药有限公司、 浙江孚诺医药股份有限公司、北京诺博特生物科技有限公司、科笛生物医药（无锡）有限公司。除公司 全资子公司西藏中卫诚康外，其他获批临床的企业还有2家：深圳珐玛易药品科技有限公司、北京逸诚 医药科技有限公司。已申报临床正在审评中的企业有2家：湖北恒安芙林药业股份有限公司、浙江和泽 医药科技股份有限公司。 截至2025年10月，公司该药品累计研发投入约人民币894.53万元（未经审计）。 根据米内网数据统计，2024年同类产品复方利多卡因乳 ...

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

北京商报讯（记者 丁宁）12月3日晚间，卫信康（603676）发布公告称，公司全资子公司西藏中卫诚康 药业有限公司收到国家药品监督管理局核准签发的利多卡因丁卡因乳膏《药物临床试验批准通知书》， 同意本品开展用于成人皮肤手术前对完整皮肤的局部麻醉的临床试验。 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-056 西藏卫信康医药股份有限公司 关于子公司获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，西藏卫信康医药股份有限公司（以下简称"公司"）全资子公司西藏中卫诚 康药业有限公司（以下简称"西藏中卫诚康"）收到国家药品监督管理局（以下简称"国 家药监局"）核准签发的利多卡因丁卡因乳膏《药物临床试验批准通知书》，现就相关事 项公告如下： 一、药物基本情况 药物名称：利多卡因丁卡因乳膏 剂型：乳膏剂 规格：每 g 含利多卡因 70mg 与丁卡因 70mg 申请事项：临床试验 受理号：CYHL2500168 主要审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 9 月 17 日受理的利多卡因丁卡因乳膏临床试验申请符合药品注册的有关要求，同意 本品开展用于成人皮肤手术前对完整皮肤的局部麻醉的临床试验。 截至 2025 年 10 月，公司该药品累计研发投入约人民币 894.53 万元（未经审计）。 根据米内网数据 ...

Core Viewpoint - Weitengkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream [1] Group 1 - The approved product, Lidocaine and Bupivacaine Cream, was developed by Zars Company and was approved by the FDA in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1]

卫信康12月3日公告，公司全资子公司西藏中卫诚康药业有限公司收到国家药品监督管理局核准签发的 利多卡因丁卡因乳膏《药物临床试验批准通知书》，同意本品开展用于成人皮肤手术前对完整皮肤的局 部麻醉的临床试验。 ...

Core Viewpoint - Weitengkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of Lidocaine and Bupivacaine Cream, marking a significant step in the development of this product for local anesthesia in adult skin surgeries [1] Group 1: Clinical Trial Approval - The NMPA approved the clinical trial application for Lidocaine and Bupivacaine Cream, which was submitted on September 17, 2025, confirming compliance with drug registration requirements [1] - The cream is intended for local anesthesia on intact skin prior to adult skin surgeries [1] Group 2: Product Background - Lidocaine and Bupivacaine Cream was developed by Zars Company and received FDA approval in the United States on June 29, 2006, under the brand name Pliaglis, with a formulation containing 70mg of Lidocaine and 70mg of Bupivacaine per gram [1] - The NMPA's 31st batch of reference preparation catalog specifies that the reference preparation for this cream is the unimported original drug approved in the U.S. Orange Book and the EU, with licensed manufacturers being Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1] - Currently, this product is not available in the domestic market [1]

利多卡因丁卡因乳膏由Zars公司研发，在2006年6月29日获美国FDA批准，商品名为Pliaglis，规格为每g 含利多卡因70mg与丁卡因70mg。国家药监局公布的第31批参比制剂目录中明确了利多卡因丁卡因乳膏 参比制剂为美国橙皮书和欧盟上市的未进口原研药品，持证商分别是Taro Pharms和Difa Cooper SPA/Galderma Laboratorium GmbH。截至目前，该产品国内暂无上市。 卫信康（603676）(603676.SH)发布公告，近日，公司全资子公司西藏中卫诚康药业有限公司(以下简 称"西藏中卫诚康")收到国家药品监督管理局(以下简称"国家药监局")核准签发的利多卡因丁卡因乳膏 《药物临床试验批准通知书》，经审查，2025年9月17日受理的利多卡因丁卡因乳膏临床试验申请符合 药品注册的有关要求，同意本品开展用于成人皮肤手术前对完整皮肤的局部麻醉的临床试验。 ...

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tibet Zhongwei Chengkang, has received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream, which is a significant development for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Development - The Lidocaine and Bupivacaine Cream was developed by Zars Company and received FDA approval in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1] - Currently, there are no domestic listings for this product in China [1] Group 2: Regulatory Approval - The National Medical Products Administration has included the Lidocaine and Bupivacaine Cream in the 31st batch of reference preparation directory, confirming its status as a reference preparation for unimported original drugs listed in the US Orange Book and the EU [1] - The licensed manufacturers for the reference preparation are Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1]